The exciting results of this clinical trial offer hope for patients who are progressing after anti-PD-1 treatment, and indicate that TIL therapy combined with a PD-1 inhibitor may be a promising choice for patients with metastatic NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.